Price
CHART BY
Frequently asked questions
What is Neurocrine's market capitalization?
The market capitalization of Neurocrine is $15.92B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Neurocrine's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Neurocrine is 22.94. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Neurocrine?
Neurocrine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $6.826. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Neurocrine's stock?
Currently, 30 analysts cover Neurocrine's stock, with a consensus target price of $210.79. Analyst ratings provide insights into the stock's expected performance.
What is Neurocrine's revenue over the trailing twelve months?
Over the trailing twelve months, Neurocrine reported a revenue of $3.37B.
What is the EBITDA for Neurocrine?
Neurocrine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $853.50M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Neurocrine?
Neurocrine has a free cash flow of $812.00M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Neurocrine have, and what sector and industry does it belong to?
Neurocrine employs approximately 2,000 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Neurocrine's shares?
The free float of Neurocrine is 100.50M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $15.92B
- EPS (TTM)
- $6.826
- Free Float
- 100.50M
- P/E ratio (TTM)
- 22.94
- Revenue (TTM)
- $3.37B
- EBITDA (TTM)
- $853.50M
- Free Cashflow (TTM)
- $812.00M
Pricing
- 1D span
- $155.82$159.36
- 52W span
- $122.15$186.12
Analyst Ratings
The price target is $210.79 and the stock is covered by 30 analysts.
Buy
27
Hold
3
Sell
0
Information
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
- Employees
- 2,000
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- NBIX
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet